Clinical Trials

Enrolling Now - 7

Protocol EP0093

An Open-Label, Multicenter, Extension Study To Evaluate the Efficacy And Safety of Padsevonil As Adjuntive Treatment of Focal-Onset Seizures In Adult Subjects with Drug-Resistant Epilepsy.

Sponsor: UCB Pharma

PI: Marcelo Lancman, MD

INCLUSION:  (all should be YES)

* Is ≥ 18 years of age? 

* Has  completed 1 of the previous PSL studies which allow access to the present Study

* Female subjects willing to follow an efficient form of contraception for the duration of the study and for a period of 3 months after their final dose of PSL.


EXCLUSION (all should be NO)

* Any lab abnormalities or subject has any severe medical, neurological, or psychiatric conditions, which may have an impact on the safety of the subjects.

* Active suicidal thoughts

* Abnormal ECg findings

* History of unexplained syncope or a family history of sudden death due to long QT interval